Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

A second monoclonal antibody to prevent respiratory syncytial virus (RSV) in infants has been recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP). Five members voted yes ...

Key Takeaways Wastewater can accurately track COVID outbreaksLevels of the COVID virus predicted case counts by about a week ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60. Health ...

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used to shape national vaccine policy has resigned, citing concerns over how ...

The CDC's vaccine advisory committee said it will study the childhood immunization schedule in the first meeting featuring HHS Secretary RFK Jr.'s hand-selected members.

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

This resource details recent developments in vaccinations, how addressing misinformation and hesitancy can improve public health, updated vaccination guidelines and more.

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.